<DOC>
	<DOCNO>NCT01001936</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability oral SKI-606 ( 100 , 200 , 300 400 mg ) administer daily schedule subject advance malignant solid tumor define maximum tolerate dose ( MTD ) subject population . This study also obtain preliminary information pharmacokinetics antitumor activity orally administer SKI-606 subject advance malignant solid tumor</brief_summary>
	<brief_title>Study Evaluating SKI-606 Subject With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Advanced recurrent solid malignancy confirm histologically cytologically effective therapy available 2 . Recovery acute adverse effect prior therapy Â£ Grade 1 ( exclude alopecia ) 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 4 . Adequate hepatic , renal , bone marrow function 5 . Age 20 74 year 6 . Willingness male female subject , surgically sterile postmenopausal , use reliable method birth control duration study 6 month 30 day last dose test article male female , respectively 7 . Life expectancy least 12 week 1 . Use systemic antitumor agent investigational agent within 28 day enrollment ( 42 day previous chemotherapy include nitrosoureas mitomycin C ) 2 . Ongoing clinical requirement administration strong inhibitor CYP3A4 3 . Prior exposure SKI606 Srckinase inhibitor 4 . Major surgery radiotherapy within 2 week enrollment ( recovery previous surgery complete day 1 ) 5 . Subjects unable unwilling swallow SKI606 capsule 6 . Active central nervous system ( CNS ) metastases , indicate clinical symptom , cerebral edema , requirement corticosteroid and/or progressive growth 7 . Recent ongoing clinicallysignificant gastrointestinal disorder 8 . Pregnant breastfeed woman 9 . Subjects meet follow criterion : Evidence serious active infection , significant medical psychiatric illness History unexplained syncope know ventricular arrythmia Known seropositivity HIV , current chronic Hepatitis B Hepatitis hepatitis C Hypokalemia Unstable concurrent medical condition Any condition , investigator 's judgment , make subject inappropriate study subject inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>PHASE 1 SKI-606 Solid tumor</keyword>
</DOC>